From GlobeNewswire:

Olema Pharmaceuticals, Inc. has announced that Sean P. Bohen, M.D., President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 9, 2024. The presentation will take place at 5:15 p.m. PT (8:15 p.m. ET) and will be available via live webcast on the company’s investor relations website at ir.olema.com for at least 30 days.

Olema Oncology is focusing on the development and commercialization of targeted therapies for women’s cancers such as palazestrant (OP-1250), a proprietary, orally-available small molecule currently being evaluated in clinical trials. This compound has been granted FDA Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer and is considered a promising treatment for such cases. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For further information, visit www.olema.com.

Vice President of Investor Relations and Communications, Geoffrey Mogilner can be contacted at [email protected] for more details about Olema Pharmaceuticals, Inc.



Read more: Olema Oncology to Present at 42nd Annual J.P. Morgan